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Objective—Some mutations in LMNA, encoding A-type lamins, are responsible for
Dunnigan-type-familial partial lipodystrophy (FPLD2), with altered fat distribution and
metabolism. The high prevalence of early and severe cardiovascular outcomes in
these patients suggests that, in addition to metabolic risk factors, FPLD2-associated
LMNA mutations could have a direct role on the vascular wall cells.
Approach and Results—We analyzed the cardiovascular phenotype of 19 FPLD2
patients aged >30 years with LMNA p.R482 heterozygous substitutions, and the
effects of p.R482W-prelamin-A overexpression in human coronary artery endothelial
cells. In 68% of FPLD2 patients, early atherosclerosis was attested by clinical
cardiovascular events, occurring before the age of 45 in most cases. In transduced
endothelial cells, exogenous wild-type-prelamin-A was correctly processed and
localized, whereas p.R482W-prelamin-A accumulated abnormally at the nuclear
envelope. Patients’ fibroblasts also showed a predominant nuclear envelope
distribution with a decreased rate of prelamin-A maturation. Only p.R482W-prelamin-
A induced endothelial dysfunction, with decreased production of NO, increased
endothelial adhesion of peripheral blood mononuclear cells, and cellular senescence.
p.R482W-prelamin-A also induced oxidative stress, DNA damages, and inflammation.
These alterations were prevented by treatment of endothelial cells with pravastatin,
which inhibits prelamin-A farnesylation, or with antioxidants. In addition, pravastatin
allowed the correct relocalization of p.R482W-prelamin-A within the endothelial cell
nucleus. These data suggest that farnesylated p.R482W-prelamin-A accumulation at
the nuclear envelope is a toxic event, leading to cellular oxidative stress and
endothelial dysfunction.
Conclusions—LMNA p.R482 mutations, responsible for FPLD2, exert a direct
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